Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

Nature

Volumn 483, Issue 7391, 2012, Pages 589-593

  Molenaar, Jan J ^a   Koster, Jan ^a   Zwijnenburg, Danny A ^a   Van Sluis, Peter ^a   Valentijn, Linda J ^a   Van Der Ploeg, Ida ^a   Hamdi, Mohamed ^a   Van Nes, Johan ^a   Westerman, Bart A ^a   Van Arkel, Jennemiek ^a   Ebus, Marli E ^a   Haneveld, Franciska ^a   Lakeman, Arjan ^a   Schild, Linda ^a   Molenaar, Piet ^a   Stroeken, Peter ^a   Van Noesel, Max M ^b   Øra, Ingrid ^a,c   Santo, Evan E ^a   Caron, Huib N ^d   Westerhout, Ellen M ^a   Versteeg, Rogier ^a   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RAC PROTEIN; RHO FACTOR;

AMINO ACID; MOLECULAR ANALYSIS; MUTATION; NERVOUS SYSTEM; NEUROLOGY; TUMOR;

ARTICLE; CANCER STAGING; CHROMOSOME ABERRATION; CHROMOTHRIPSIS; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC DISORDER; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; NEURITOGENESIS; NEUROBLASTOMA; NEUROPATHOLOGY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AGING; CHROMOSOMES, HUMAN; CLUSTER ANALYSIS; DNA HELICASES; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GROWTH CONES; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MUTATION; NEOPLASM STAGING; NEURITES; NEUROBLASTOMA; NUCLEAR PROTEINS; PROGNOSIS; RAC GTP-BINDING PROTEINS; RHO GTP-BINDING PROTEINS;

EID: 84859216598     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10910     Document Type: Article

References (36)

1. Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202-2211 (2010).
2. Mossé, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
3. George, R. E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
4. Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
5. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
6. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
7. Kraus, D. M. et al. CSMD1 is a novel multiple domain complement- regulatory protein highly expressed in the central nervous system and epithelial tissues. J. Immunol. 176, 4419-4430 (2006).
8. Sun, Q. L. et al. Growth cone steering by receptor tyrosine phosphatase delta defines a distinct class of guidance cue. Mol. Cell. Neurosci. 16, 686-695 (2000).
9. Zheng, L. et al. Drosophila Ten-m and filamin affect motor neuron growth cone guidance. PLoS ONE 6, e22956 (2011).
10. Chen, Q. R. et al. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics 5, 70 (2004).
11. Vandesompele, J. et al. Multicentre analysis of patterns of DNA gains and losses in 204neuroblastomatumors: howmany genetic subgroups are there?Med. Pediatr. Oncol. 36, 5-10 (2001).
12. Janoueix-Lerosey, I. et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 27, 1026-1033 (2009).
13. Drmanac, R. et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81 (2010).
14. Parsons, D. W. et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435-439 (2011).
15. Leeuwen, F. N. et al. The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho. J. Cell Biol. 139, 797-807 (1997).
16. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nature Methods 7, 248-249 (2010).
17. Kee, Y. & D'Andrea, A. D. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 24, 1680-1694 (2010).
18. E. E. & Santo, et a. l. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene advance online publication doi:10.1038/onc.2011.344 (22 August 2011).
19. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199-1203 (2011).
20. Law, M. J. et al. ATR-X syndrome protein targets tandemrepeats and influences allele-specific expression in a size-dependent manner. Cell 143, 367-378 (2010).
21. Arregui, C. O., Balsamo, J. & Lilien, J. Regulation of signaling by protein-tyrosine phosphatases: potential roles in the nervous system. Neurochem. Res. 25, 95-105 (2000).
22. Rubin, B. P. et al. Teneurins: a novel family of neuronal cell surface proteins in vertebrates, homologous to the Drosophila pair-rule gene product Ten-m. Dev. Biol. 216, 195-209 (1999).
23. Stallings, R. L. et al. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res. 66, 3673-3680 (2006).
24. Matsuo, N. et al. Roles of STEF/Tiam1, guanine nucleotide exchange factors for Rac1, in regulation of growth cone morphology. Mol. Cell. Neurosci. 24, 69-81 (2003).
25. Nishimura, T. et al. PAR-6-PAR-3mediatesCdc42-inducedRac activation through the Rac GEFs STEF/Tiam1. Nature Cell Biol. 7, 270-277 (2005).
26. Bar-Sagi, D. & Hall, A. Ras and Rho GTPases: a family reunion. Cell 103, 227-238 (2000).
27. Shioda, N. et al. Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain. J. Neurosci. 31, 346-358 (2011).
28. Valentijn, L. J. et al. Inhibition of a newdifferentiation pathway in neuroblastomaby copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res. 65, 3136-3145 (2005).
29. Matthay, K. K. et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol. 27, 1007-1013 (2009).
30. Hö lzel M. et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142 218-229 (2010).
31. Molenaar, J. J., van Sluis, P., Boon, K., Versteeg, R. & Caron, H. N. Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosom. Cancer 36, 242-249 (2003).
32. Thiele, C. J. In Human Cell Culture vol. 1 (ed. Masters, J.) 21-53 (1998).
33. Bewick, V., Cheek, L. & Ball, J. Statistics review 12: survival analysis. Crit. Care 8, 389-394 (2004).
34. Maere, S., Heymans, K. & Kuiper, M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21, 3448-3449 (2005).
35. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P.-L. & Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27, 431-432 (2011).
36. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large genelists usingDAVIDbioinformatics resources.Nature Protocols 4,44-57 (2008).